Author: Author

Solvay Brussels School of Economics and Management Joins Forces with the Belgian Life Sciences Ecosystem to Train the Next Generation of Biotech and MedTech Leaders
March 31, 2022 Off

Solvay Brussels School of Economics and Management Joins Forces with the Belgian Life Sciences Ecosystem to Train the Next Generation of Biotech and MedTech Leaders

By Author

The Solvay Brussels School of Economics and Management in collaboration with the ULB research institute I3h has  launched a new Advanced Master in Biotech & MedTech Ventures. The programme addresses the thriving Belgian and European life sciences’ need for young entrepreneurial talent capable of taking on (C-level) management positions in early-stage Biotech and MedTech companies.

Symbiosis​ Successfully Completes UK Research and Innovation (UKRI) Project
March 30, 2022 Off

Symbiosis​ Successfully Completes UK Research and Innovation (UKRI) Project

By Author

Symbiosis Pharmaceutical Services Ltd, a contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has completed a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease
March 30, 2022 Off

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease

By Author

Scenic Biotech BV (‘Scenic’ or ‘the Company’), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, and the Barth Syndrome Foundation (BSF or ‘the Foundation’), have entered into a partnership to support the advancement of Scenic’s in-house drug discovery program to find novel tailored treatments for Barth syndrome, a devastating multi-system disorder that leads to complex clinical manifestations and significantly reduced life expectancy.

FDA Approves Moderna’s Second Booster
March 29, 2022 Off

FDA Approves Moderna’s Second Booster

By Author

Moderna, Inc. (NASDAQ:MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization (EUA) to allow for a second booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise.

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
March 19, 2022 Off

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

By Author

Opdualag, a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio.